| Item | NexLife | Noom Med |
|---|---|---|
| What you get | Compounded semaglutide and tirzepatide (not FDA-approved) | Compounded semaglutide and tirzepatide (not FDA-approved); brand drugs through insurance |
| Program or membership fee | None (“No memberships or contracts”) | Included (“All-inclusive pricing”) |
| Medication included in that price | Yes: medication, medical guidance from NexLife Medical Group, nutrition plan, coaching call, 24/7 support, shipping | Yes, on its compounded programs |
| Pharmacies named | Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux’s New Drug Store (Lake Charles, LA): 503A on its plan pages; its FAQ names two | Not named (“available through Noom-GLP1”) |
| 12-month arithmetic | Tirzepatide: $115 × 12 = $1,380. Semaglutide: $95 × 12 = $1,140 (12-month plans). | Semaglutide: $129 + 11 × $249 = $2,868. Tirzepatide: $149 + 11 × $299 = $3,438. A footnote prices semaglutide at $279 a month ($837 per 12 weeks). |
| Price read status | Re-read November 6, 2026 (nexlife.us) | Re-read November 20, 2026 (noom.com/med/pricing) |
| Score | 86/100 (v4.1 methodology) | 56/100 (v4.1 score from pages read November 20, 2026) |
Who each program fits
Noom Med may fit if you want a behavior-change app with a lower-dose program.
NexLife may fit if you want a compounded GLP-1 at a fixed monthly price that does not rise with the dose, with the pharmacy named before you pay. Price check: Mondae ($126 tirzepatide, $87 semaglutide) lists lower month-to-month prices, and Eden Health ($99) a lower semaglutide price.
Brand medications such as Wegovy and Zepbound are FDA-approved; compounded semaglutide and tirzepatide are not FDA-approved and are not the same products.
What this comparison cannot tell you
We compared published prices and terms, not clinical quality. We did not enroll with either program, so intake-only fees, the pharmacy on a given shipment and dose-specific prices shown after checkout were not visible. Confirm each figure on the program’s own page before paying.